Atopic dermatitis
Drug research and approvals for atopic dermatitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 186 studies of atopic dermatitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 206 drug trials for it since 2013, and the EU has 7 authorised medicines for it.
- Recruiting worldwide: 186
- Trials authorized in Canada: 206
- FDA orphan approvals: 0
- EU medicines: 7
- Gut Microbiome Diversity in Adults With Inflammatory and Immune-Mediated Skin DiseasesNCT07944196 · Not reported · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · starts Apr 11, 2026
- The LITTLE OWLS Study (in German: "Kleine Eulen OWL"): Exploring the Early-life Microbiome Development and Physical and…NCT07934654 · Not reported · Bielefeld University · starts Mar 1, 2024
- Roflumilast Cream 0.3% for Moderate to Severe Atopic DermatitisNCT07916480 · Phase 3 · Arcutis Biotherapeutics, Inc. · starts Oct 30, 2026
- A Study for AR100DP1 in Mild to Moderate Atopic DermatitisNCT07914088 · Phase 2 · Arjil Pharmaceuticals LLC · starts Oct 21, 2026
- Observational Analytical Validation Study of the Replior ScratchSenseNCT07909967 · Not reported · Replior AB · starts Oct 12, 2026
- ADBest TREAT RegistryNCT07904546 · Not reported · Universitätsklinikum Hamburg-Eppendorf · starts Jan 1, 2023
- Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With…NCT07895615 · Phase 2 · Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · starts Oct 1, 2026
- PRA-216 Atopic Dermatitis Safety and Efficacy StudyNCT07810777 · Phase 2 · Prana Therapies Inc · starts Sep 17, 2026
- Changes in Skin Myco- and Microbiome After Lebrikizumab TreatmentNCT07807228 · Not reported · University Hospital Bispebjerg and Frederiksberg · starts Jun 5, 2025
Approved 17
- DupilumabInterleukin-4 receptor subunit alpha antagonist
- PimecrolimusFK506-binding protein 1A inhibitor
- TralokinumabInterleukin-13 inhibitor
- CrisaborolePhosphodiesterase 4 inhibitor
- LebrikizumabInterleukin-13 inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- AbrocitinibTyrosine-protein kinase JAK1 inhibitor
- Hydrocortisone butyrateGlucocorticoid receptor agonist
- DesonideGlucocorticoid receptor agonist
- Fluticasone propionateGlucocorticoid receptor agonist
- PrednisoneGlucocorticoid receptor agonist
- DoxepinNorepinephrine transporter inhibitor
- PromethazineHistamine H1 receptor antagonist
- IpratropiumMuscarinic acetylcholine receptor M3 antagonist
- Dexamethasone phosphoric acidGlucocorticoid receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
- Fluocinolone acetonideGlucocorticoid receptor agonist
Phase 3 12 of 22
- RuxolitinibTyrosine-protein kinase JAK1 inhibitor
- UpadacitinibTyrosine-protein kinase TYK2 inhibitor
- DifamilastPhosphodiesterase 4 inhibitor
- RocatinlimabTumor necrosis factor receptor superfamily member 4 antagonist
- BaricitinibTyrosine-protein kinase JAK1 inhibitor
- AmlitelimabTumor necrosis factor ligand superfamily member 4 inhibitor
- Stapokibart
- NemolizumabInterleukin-31 receptor subunit alpha inhibitor
- RoflumilastPhosphodiesterase 4 inhibitor
- CyclosporineCyclophilin A modulator
- TapinarofAryl hydrocarbon receptor agonist
- PAC-14028Vanilloid receptor antagonist
Phase 2 12 of 69
- ApremilastPhosphodiesterase 4 inhibitor
- Dihomo-gamma-linolenic acid
- FB-825
- Mometasone furoateGlucocorticoid receptor agonist
- PegcantratinibNerve growth factor receptor Trk-A inhibitor
- TezepelumabThymic stromal lymphopoietin inhibitor
- LotamilastPhosphodiesterase 4 inhibitor
- Ocankitug
- CholecalciferolVitamin D receptor agonist
- Hydrocortisone acetateGlucocorticoid receptor agonist
- TriamcinoloneGlucocorticoid receptor agonist
- IvermectinGlutamate-gated chloride channel modulator
Phase 1 or earlier 12 of 23
- MetoprololBeta-1 adrenergic receptor antagonist
- OmalizumabIg epsilon chain C region inhibitor
- WarfarinVitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
- OmeprazolePotassium-transporting ATPase inhibitor
- CaffeineAdenosine receptor antagonist
- Clobetasol propionateGlucocorticoid receptor agonist
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- ClonidineAdrenergic receptor alpha-2 agonist
- GentamicinBacterial 70S ribosome inhibitor
- NortriptylineSerotonin transporter inhibitor
- TofacitinibJanus Kinase (JAK) inhibitor
- NaltrexoneOpioid receptors; mu/kappa/delta antagonist
How its trials ended
1,201 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 299 whose ending is known, 51% met their primary endpoint, 4% missed it and 44% stopped early.
- Completed, result not reported56247%
- Ongoing24721%
- Met its primary endpoint15313%
- Status unknown938%
- Stopped: other or unclear615%
- Stopped: lack of efficacy242%
- Stopped: enrollment or feasibility222%
- Stopped: sponsor or business decision202%
- Missed its primary endpoint131%
- Stopped: funding6<1%
| Sep 16, 2026 | A phase 3, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin (NKTR-358) monotherapy…Rezpegaldesleukin (NKTR-358) | Nektar Therapeutics | Pending |
| Sep 10, 2026 | A randomized, double-blind, parallel group, placebo-controlled phase 3 combination therapy study to investigate the efficacy & safety oftilrekimig in adult &…Tilrekimig (PF-07275315) | Pfizer | Ongoing |
| Sep 2, 2026 | A phase 3, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin (NKTR-358) monotherapy…Rezpegaldesleukin (NKTR-358) | Nektar Therapeutics | Ongoing |
| Sep 2, 2026 | A phase 3, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin (NKTR-358) monotherapy…Rezpegaldesleukin (NKTR-358) | Nektar Therapeutics | Ongoing |
| Aug 12, 2026 | A phase 2, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy, safety, and pharmacokinetics of multiple subcutaneous…TRIV-573 | Triveni Bio, Inc. | Pending |
| Jun 18, 2026 | A phase 2 multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and preliminary efficacy of soquelitinib in…Soquelitinib (CPI-818) | Corvus Pharmaceuticals | Ongoing |
| Jun 8, 2026 | A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the efficacy and safety of ENV-294 in adult…ENV-294 | Enveda Therapeutics | Pending |
| Jun 4, 2026 | A long-term extension study to evaluate the safety and efficacy of subcutaneous IMG-007 in participants of a previous IMG-007 moderate-to-severe atopic…IMG-007 | Inmagene LLC | Ongoing |
| Apr 9, 2026 | A phase 2b, multicenter, randomized, doubleblind, placebo-controlled study to evaluate the efficacy and safety of camoteskimab in adults with…Camoteskimab (APL-9109) | Apollo Therapeutics, Limited | Ongoing |
| Dec 19, 2025 | A phase 2b, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of JNJ-95597528 for the treatment…JNJ-95597528 | Johnson & Johnson | Ongoing |
| Feb 12, 2025 | NemluvioNemolizumab | Galderma International | EMA ↗ |
| Nov 16, 2023 | EbglyssLebrikizumab | Almirall, S.A. | EMA ↗ |
| Apr 19, 2023 | OpzeluraRuxolitinib | Incyte Biosciences Distribution B.V. | EMA ↗ |
| Dec 9, 2021 | CibinqoAbrocitinib | Pfizer Europe MA EEIG | EMA ↗ |
| Jun 17, 2021 | AdtralzaTralokinumab | LEO Pharma A/S | EMA ↗ |
| Sep 26, 2017 | DupixentDupilumab | Sanofi Winthrop Industrie | EMA ↗ |
| Feb 27, 2002 | ProtopicTacrolimus | LEO Pharma A/S | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA